ANA Spotlights

Virtual product theater presentations on neurology and neuroscience, brought to you by industry leaders

Please see our featured Spotlights below!

Interested in creating an ANA Spotlights presentation? Learn more about all sponsorship opportunities here or Contact Carole Bernstein for information.

Disclaimer: The ANA Spotlights videos are paid advertisements and viewers are not to consider the contents as an endorsement of products or services by the ANA. The materials, information or opinions provided during the videos are solely those of the individuals and companies involved and do not necessarily represent those of the ANA.

ANA Spotlights

Latest Module

Stoke Therapeutics: Treatment outcomes of STK-001 for Dravet syndrome

In this video, Dr Scott Perry, MD of Cook Children’s Medical Center presents data from multiple ongoing clinical studies that support the potential of STK-001, an antisense oligonucleotide, as the first disease-modifying treatment for Dravet...
Episode Description

In this video, Dr Scott Perry, MD of Cook Children’s Medical Center presents data from multiple ongoing clinical studies that support the potential of STK-001, an antisense oligonucleotide, as the first disease-modifying treatment for Dravet syndrome. This presentation was recorded at the 2023 International Epilepsy Congress. For additional information about STK-001 or Stoke Therapeutics, please contact Stoke Therapeutics at Medicalinformation@stoketherapeutics.com or visit www.stoketherapeutics.com/

Featuring
  • Guest: Dr. Scott Perry, Cook Children’s Medical Center
Read Full Episode Description

NMD Symposium: The role of neuromuscular transmission failure and ClC-1 inhibition as a novel therapeutic approach across neuromuscular diseases; positive proof of mechanism in patients with myasthenia gravis

Recorded at ANA2023
Episode Description

In a group of neuromuscular diseases, dysfunctions that cause excitation failures of muscle fiber action potential at the neuromuscular junction (NMJ) lead to excessive and, in some cases, life-threatening muscle weakness. Multiple cellular mechanisms can cause NMJ transmission failure in these diseases, commonly affecting the release of acetylcholine from pre-synaptic nerve terminals or the post-synaptic ability of muscle fibers to respond to that release.


During this symposium, we will examine how different neuromuscular diseases affect the NMJ transmission including spinal muscular atrophy, Charcot-Marie Tooth and myasthenia gravis. We will review current clinical evidence of these abnormalities in patients, their correlation with the severity of their symptoms and the potential of skeletal muscle-specific ClC-1 ion channels inhibition to correct these deficits.


Unpublished data results from a proof of mechanism study utilizing a novel and first in class ClC-1 inhibitor in patients with myasthenia gravis will be presented and discussed; patients enrolled in a randomized, double-blind, placebo-controlled, three-way crossover study received a ClC-1 inhibitor and demonstrated clinically relevant improvements.

Featuring
  • Guest: Dr. W. David Arnold, University of Missouri
  • Guest: Dr. Thomas H. Pedersen, NMD Pharma
  • Guest: Dr. Jorge A. Quiroz, NMD Pharma
Read Full Episode Description

Eisai Inc. Symposium: Alzheimer's disease: an expert discussion on the evolving treatment landscape

Recorded at ANA2023
Alzheimer's disease: an expert discussion on the evolving treatment landscape
Featuring
  • Guest: Jessica Zweling, MD, MS, FAAN
  • Guest: Darren Gitelman, MD, FAAN, FANA
Read Full Episode Description

ANA Spotlights Mayo Clinic's Jeremy Cutsforth-Gregory, MD, FAAN Assistant Professor of Neurology Director, CSF Dynamics Clinic

In this ~5 minute video, Dr. Jeremy Cutsforth-Gregory, MD, FAAN of Mayo Clinic's Neurology team reviews a pioneering procedure to reduce the procedural risk and greatly improve the outcome for patients with CSF venous fistula.
Episode Description

In this ~5 minute video, Dr. Jeremy Cutsforth-Gregory, MD, FAAN of Mayo Clinic's Neurology team reviews a pioneering procedure to reduce the procedural risk and greatly improve the outcome for patients with CSF venous fistula.

Please follow these links to learn more about Dr. Cutsforth-Gregory and collaborating with Mayo Clinic's Neurology & Neurosurgery teams:

Mayo Clinic Neurology and Neurosurgery Referrals

Jeremy Cutsforth-Gregory, M.D., FAAN Biographical Summary

Featuring
  • Interviewer/Producer: Dr. Jeremy Custforth-Gregory, MD, FAAN, Mayo Clinic's Neurology team
Read Full Episode Description

ANA Spotlights Mayo Clinic's Andrew McKeon, M.B., B.Ch., M.D.

In this 30 minute video, Dr. Andrew McKeon of Mayo Clinic's Neurology team discusses the rationale and benefits of collaborating with the Mayo Clinic team in the diagnosis of autoimmune CNS disorders.

Please follow these links to learn more abo
Episode Description

In this 30 minute video, Dr. Andrew McKeon of Mayo Clinic's Neurology team discusses the rationale and benefits of collaborating with the Mayo Clinic team in the diagnosis of autoimmune CNS disorders.

Please follow these links to learn more about Dr. McKeon and collaborating with Mayo Clinic's Neurology & Neurosurgery teams:

Mayo Clinic Neurology and Neurosurgery Referrals

Jeremy Cutsforth-Gregory, M.D., FAAN Biographical Summary

Featuring
  • Interviewer/Producer: Dr. Andrew McKeon, M.B., B.CH., M.D., Mayo Clinic's Neurology & Neurosurgery teams
Read Full Episode Description